AR and breast carcinoma: Furthermore, AR has emerged as a potential therapeutic target in breast cancer and its efficacy in AR+-TNBC (Stage I–III) patients is currently under evaluation, based on a protocol with enzalutamide (Enza) and paclitaxel (Px) before surgery (clinical trial NCT02689427).